In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 80 days of free consultation

 

Impact of the gender difference on long-term clinical outcomes in dyslipidemic South Korean AMI patients who underwent PCI with new-generation DES

Session Poster Session 6

Speaker Yong Hoon Kim

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P5494

Authors : YH Kim (Chuncheon,KR), A-Y Her (Chuncheon,KR), M-H Jeong (Gwangju,KR), B-K Kim (Seoul,KR), S-Y Lee (Gunpo,KR), S-J Hong (Seoul,KR), D-H Shin (Seoul,KR), C-M Ahn (Seoul,KR), J-S Kim (Seoul,KR), Y-G Ko (Seoul,KR), D Choi (Seoul,KR), M-K Hong (Seoul,KR), Y Jang (Seoul,KR)

Authors:
YH Kim1 , A-Y Her1 , M-H Jeong2 , B-K Kim3 , S-Y Lee4 , S-J Hong3 , D-H Shin3 , C-M Ahn3 , J-S Kim3 , Y-G Ko3 , D Choi3 , M-K Hong3 , Y Jang3 , 1Kangwon National University School of Medicine - Chuncheon - Korea (Republic of) , 2Chonnam National University Hospital, Department of Cardiology - Gwangju - Korea (Republic of) , 3Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine - Seoul - Korea (Republic of) , 4Sanbon Hospital, Wonkwang University College of Medicine, Department of Cardiology - Gunpo - Korea (Republic of) ,

Citation:

Background: There are limited comparative data concerning long-term major clinical outcomes between male and female in dyslipidemic AMI patients after PCI with new-generation DES.

Purpose: We thought to investigate the impact of gender difference on the 2-year clinical outcomes.

Methods: Finally, a total of 2403 eligible dyslipidemic AMI patients who underwent PCI with new-generation DES were enrolled and they were separated into two groups; the male group (n = 1800) and the female group (n = 603). The primary endpoint was major adverse cardiac events (MACE) defined as all-cause death, recurrent myocardial infarction (re-MI), target lesion revascularization (TLR), and target vessel revascularization (TVR). The secondary endpoints were the incidence of the individual components of MACE and target vessel failure (TVF), a composite of death related to the target vessel, re-MI, or clinically driven TVR

Results: Two propensity score-matched (PSM) groups (422 pairs, n = 844, C-statistic = 0.850) were generated. In the total study population, the cumulative incidences of MACE, all-cause death, re-MI, and TVF were significantly higher in the female group compared with the male group. However, after propensity score-matched (PSM) analysis, the cumulative incidences of MACE (HR, 0.971; 95% CI, 0.628–1.501; p = 0.895), all-cause death (HR, 1.061; 95% CI, 0.536–2.100; p = 0.865), re-MI (HR, 1.212; 95% CI, 0.433–2.907; p = 0.813), and TVF (HR, 0.764; 95% CI, 0.474–1.229; p = 0.267) were similar between the two groups. In addition, the cumulative incidences of cardiac death, TLR, TVR were not significantly different between the two groups (Table 1).

Conclusion: The gender difference was not apparent in these dyslipidemic South Korean AMI patients who underwent PCI with new-generation DES during 2-year follow-up period.

Cumulative Events at 2-year (%)

Outcomes

Male

Female

Log-rank

Hazard Ratio (95% CI)

p value

Propensity score matched Patients

MACE

41 (10.4)

40 (10.3)

0.895

0.971 (0.628 - 1.501)

0.895

All-cause death

16 (4.0)

17 (4.2)

0.865

1.061 (0.536 - 2.100)

0.865

Cardiac death

13 (3.3)

9 (2.2)

0.391

0.691 (0.295 - 1.616)

0.393

Re-MI

8 (2.0)

9 (2.4)

0.813

1.212 (0.433 - 2.907)

0.813

TLR

7 (1.8)

6 (1.6)

0.781

0.857 (0.298 - 2.550)

0.781

TVR

16 (4.3)

10 (2.7)

0.236

0.623 (0.283 - 1.373)

0.241

TVF

39 (10.2)

30 (7.8)

0.265

0.764 (0.474 - 1.229)

0.267



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are